Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCrimson Tide Regulatory News (TIDE)

Share Price Information for Crimson Tide (TIDE)

Share Price is delayed by 15 minutes
Get Live Data
92.50    5.00 (5.71%)
Bid:
90.00
Ask:
95.00
Spread: 5.00 (5.556%)
Market Cap: £6.08m
TIDE Live PriceLast checked at - London Stock Exchange

Intraday Crimson Tide Share Chart

Pharmaceutical Verification Pilot

14 Jul 2016 07:00

RNS Number : 1316E
Crimson Tide PLC
14 July 2016
 

Crimson Tide PLC

 

("Crimson Tide" or the 'Company')

 

Crimson Tide selected for pharmaceutical verification pilot

 

Crimson Tide (TIDE), the AIM-quoted provider of mpro5 - Smart Mobility as a Service, has won a contract for the initial stage of a significant healthcare pilot project in Asia for the serialisation and verification of pharmaceutical products. The pilot project is being implemented under the auspices of the Asia Pacific Economic Cooperation (APEC) Life Sciences Innovation Forum (LSIF), Committee on Trade and Investment (CTI) and Business Advisory Council (ABAC).

 

Selected by a consortium of pharma organisations, the technology platform for the demonstration phase of the pilot project will leverage mpro5 to scan pharmaceutical products, generating an anonymous verification request to the product's manufacturer. The pilot project seeks to demonstrate for the first time the ability to verify serialised pharmaceutical products from various scan locations to source data stored in distributed databases using global data standards. The pilot also seeks to promote harmonisation by demonstrating the ability to use a single or reproducible data gateway in multiple countries.

 

mpro5 provides barcode scanning and cloud-based synchronisation services via Microsoft Azure, renowned for its reliability, scalability and security. This enables real-time information upload, quick verifications and multi-way data request transmittals.

 

Barrie Whipp, Executive Chairman of Crimson Tide, said: "The global impact of drug serialisation and verification cannot be underestimated. I am delighted that we have been chosen to help in this pilot project in Asia, as it opens up significant opportunities in the pharma world."

 

ends

 

For further information:

 

Crimson Tide plc

 

Barrie Whipp 01892 542 444

Steve Goodwin

 

WH Ireland

 

James Joyce /James Bavister 020 7220 1666

Allerton Communications

Peter Curtain 020 3137 2500

peter.curtain@allertoncomms.co.uk 

 

Notes to editors

Founded in 1996 and quoted on AIM since 2006, Crimson Tide plc is the provider of mpro5 - Smart Mobility as a Service (SMaaS). mpro5 is delivered on smartphones, tablets and PDAs, and enables companies to transform their businesses and strengthen their workforces.

Crimson Tide offers a global service, working with some of the world's leading companies, tailoring mpro5 to suit customer needs. Developed over 10 years by its world-class team, mpro5 is the smart choice for organisations large and small that want to improve productivity and save money.

mpro5 is a platform-agnostic mobility suite fully hosted on Microsoft Azure, so customers are quickly up and running and the service is scalable and robust. It is provided on subscription, so clients can immediately see a return on their investment.

mpro5 not only helps people improve their day-to-day working methods while saving employers money, it also saves lives, by enabling haemophilia patients to verify the safety of their medication before use. mpro5 clients come from a diverse range of industries allowing the Company to listen, share and find the best solution for all mobility needs.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
CNTEAPXDFFLKEFF
Date   Source Headline
4th Jan 20235:00 pmRNSHolding(s) in Company
1st Dec 20227:00 amRNSDirector dealing
17th Nov 20227:00 amRNSSignificant contract expansion and extension
27th Sep 20227:00 amRNSInterim Results
25th Aug 20227:00 amRNSDirector Dealing
3rd Aug 20227:00 amRNSChange of Auditor
2nd Aug 20227:00 amRNSBoard Changes
25th Jul 20227:00 amRNSContract Win
19th Jul 20227:00 amRNSMultiyear contract win with major wholesaler
30th Jun 202211:27 amRNSResults of AGM & Statement
16th Jun 20224:30 pmRNSAnnual Report and Notice of AGM
7th Apr 20227:00 amRNSPreliminary Results
10th Feb 20227:00 amRNSContract Win and Strategic Partnership
3rd Feb 20227:00 amRNSTrading Update
7th Dec 20217:00 amRNSMaster Service Agreement with Compass Group
12th Nov 20217:00 amRNSDirectorate Change
11th Oct 202110:59 amRNSPDMR Dealing
28th Sep 20217:00 amRNSInterim Results
29th Jun 20213:08 pmRNSResult of AGM
16th Jun 20217:00 amRNSNorth America Appointment
4th Jun 20217:00 amRNSAnnual Report and Notice of AGM
4th May 20212:22 pmRNSTotal Voting Rights
28th Apr 202110:34 amRNSHolding(s) in Company
27th Apr 20217:00 amRNSHolding(s) in Company
26th Apr 20217:00 amRNSHolding(s) in Company
23rd Apr 20214:25 pmRNSHolding(s) in Company
23rd Apr 202110:37 amRNSPDMR Dealings
23rd Apr 202110:36 amRNSHolding(s) in Company
22nd Apr 202111:45 amRNSResult of General Meeting and Total Voting Rights
20th Apr 20217:00 amRNSContract Win
1st Apr 20213:52 pmRNSResult of Placing
1st Apr 202112:01 pmRNSPlacing to raise up to £6.0 million
1st Apr 202112:00 pmRNSPreliminary Results
18th Mar 20217:00 amRNSContract Win
1st Feb 20219:28 amRNSHolding(s) in Company
28th Jan 20217:00 amRNSAppointment of Director
26th Jan 20217:00 amRNSPilot with World Federation of Haemophilia
18th Jan 20219:36 amRNSHolding(s) in Company
12th Jan 20214:07 pmRNSHolding(s) in Company
7th Jan 20212:30 pmRNSHolding(s) in Company
23rd Dec 202012:15 pmRNSClarification re Grant of Options
22nd Dec 202010:45 amRNSGrant of Options under the Company's EMI Scheme
4th Dec 202011:35 amRNSHolding(s) in Company
17th Nov 20207:00 amRNSContract Wins
12th Nov 20204:27 pmRNSDirector/PDMR Shareholding
6th Nov 20201:15 pmRNSPDMR dealing
26th Oct 202010:08 amRNSHolding(s) in Company
5th Oct 20209:16 amRNSHolding(s) in Company
18th Sep 20207:00 amRNSInterim Results
14th Sep 20202:06 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.